APX-3330 is under clinical development by Apexian Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how APX-3330’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

APX-3330 overview

APX-3330 is under development for the treatment of solid tumors including pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma, endometrial cancer, melanoma, chronic hepatitis C, prostate cancer and colorectal cancer, diabetic macular edema, non proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), hematological cancers including acute lymphoblastic leukemia, malignant peripheral nerve sheath tumor (MPNST), laser-induced choroidal neovascularization, tuberous sclerosis complex (TSC), inflammation, inflammatory bowel disease, wet age-related macular degeneration, gall bladder cancer, hepatocellular cancer, bladder cancer and ovarian cancer. It is a new chemical entity and is administered orally as a tablet. The drug candidate acts by targeting Ref-1 and TNF synthesis.

It was also under development for the treatment of hepatic failure and chemotherapy-induced peripheral neuropathy.

Apexian Pharmaceuticals overview

Apexian Pharmaceuticals is a clinical-stage biotechnology company.It develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases. The company is headquartered in Indianapolis, Indiana, United States.

For a complete picture of APX-3330’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.